ALNY vs. NVO: Alnylam Pharmaceuticals vs. Novo Nordisk Stock Comparison

Company Profile

Alnylam Pharmaceuticals (ALNY) and Novo Nordisk (NVO) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ALNY is classified in Biotechnology while NVO is classified in Pharmaceuticals.

Alnylam Pharmaceuticals (ALNY) trades as ordinary local shares, while Novo Nordisk (NVO) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both companies show strong equity returns, but Alnylam Pharmaceuticals (ALNY) at 138.07% is the standout with ROE above its industry range; Novo Nordisk (NVO) at 58.38% also sits in the top quartile.

Both Alnylam Pharmaceuticals (ALNY) at 52.85% and Novo Nordisk (NVO) at 33.92% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

Both Alnylam Pharmaceuticals (ALNY) at 23.72% and Novo Nordisk (NVO) at 40.05% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Alnylam Pharmaceuticals (ALNY) at 65.19% sits in the top revenue growth quartile, while Novo Nordisk (NVO) at 6.43% is closer to the peer norm — faster top-line expansion for ALNY.

Only one side can be read here: Novo Nordisk (NVO) reports EPS growth of 1.77%, ranked against its industry; Alnylam Pharmaceuticals (ALNY) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Alnylam Pharmaceuticals (ALNY) at 2.48 keeps current ratio within its industry’s typical mid-range, while Novo Nordisk (NVO) at 0.85 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for NVO.

Novo Nordisk (NVO) at 0.62 carries an industry-typical debt-to-equity mix, while Alnylam Pharmaceuticals (ALNY) at 0.83 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Alnylam Pharmaceuticals (ALNY) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Novo Nordisk (NVO) reports a yield of 29.03%, ranking against industry peers normally.

Alnylam Pharmaceuticals (ALNY) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Novo Nordisk (NVO) reports a payout of 45.36%, ranking against industry peers normally.

Dividend Metrics

Valuation

Both Alnylam Pharmaceuticals (ALNY) at 7.88 and Novo Nordisk (NVO) at 10.18 sit in the cheaper earnings-multiple quartile for P/E ratio, with the market paying less for a dollar of trailing earnings than it pays for typical peers.

Novo Nordisk (NVO) at 0.53 sits in the cheaper P/S ratio quartile while Alnylam Pharmaceuticals (ALNY) at 4.17 prices around its industry’s middle — NVO costs less per dollar of sales, though read it alongside growth and margins.

On P/B ratio, both Alnylam Pharmaceuticals (ALNY) at 5.79 and Novo Nordisk (NVO) at 5.43 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics